These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 34568006)

  • 1. High-Affinity Chimeric Antigen Receptor With Cross-Reactive scFv to Clinically Relevant EGFR Oncogenic Isoforms.
    Thokala R; Binder ZA; Yin Y; Zhang L; Zhang JV; Zhang DY; Milone MC; Ming GL; Song H; O'Rourke DM
    Front Oncol; 2021; 11():664236. PubMed ID: 34568006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival.
    Genßler S; Burger MC; Zhang C; Oelsner S; Mildenberger I; Wagner M; Steinbach JP; Wels WS
    Oncoimmunology; 2016 Apr; 5(4):e1119354. PubMed ID: 27141401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective Targeting of Glioblastoma with EGFRvIII/EGFR Bitargeted Chimeric Antigen Receptor T Cell.
    Jiang H; Gao H; Kong J; Song B; Wang P; Shi B; Wang H; Li Z
    Cancer Immunol Res; 2018 Nov; 6(11):1314-1326. PubMed ID: 30201736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts.
    Ohno M; Ohkuri T; Kosaka A; Tanahashi K; June CH; Natsume A; Okada H
    J Immunother Cancer; 2013; 1():21. PubMed ID: 24829757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma.
    Johnson LA; Scholler J; Ohkuri T; Kosaka A; Patel PR; McGettigan SE; Nace AK; Dentchev T; Thekkat P; Loew A; Boesteanu AC; Cogdill AP; Chen T; Fraietta JA; Kloss CC; Posey AD; Engels B; Singh R; Ezell T; Idamakanti N; Ramones MH; Li N; Zhou L; Plesa G; Seykora JT; Okada H; June CH; Brogdon JL; Maus MV
    Sci Transl Med; 2015 Feb; 7(275):275ra22. PubMed ID: 25696001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor efficacy of chimeric antigen receptor T cells against EGFRvIII-expressing glioblastoma in C57BL/6 mice.
    Chen M; Sun R; Shi B; Wang Y; Di S; Luo H; Sun Y; Li Z; Zhou M; Jiang H
    Biomed Pharmacother; 2019 May; 113():108734. PubMed ID: 30849636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenalidomide enhances the function of chimeric antigen receptor T cells against the epidermal growth factor receptor variant III by enhancing immune synapses.
    Kuramitsu S; Ohno M; Ohka F; Shiina S; Yamamichi A; Kato A; Tanahashi K; Motomura K; Kondo G; Kurimoto M; Senga T; Wakabayashi T; Natsume A
    Cancer Gene Ther; 2015 Oct; 22(10):487-95. PubMed ID: 26450624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma.
    Sahin A; Sanchez C; Bullain S; Waterman P; Weissleder R; Carter BS
    PLoS One; 2018; 13(7):e0199414. PubMed ID: 29975720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.
    O'Rourke DM; Nasrallah MP; Desai A; Melenhorst JJ; Mansfield K; Morrissette JJD; Martinez-Lage M; Brem S; Maloney E; Shen A; Isaacs R; Mohan S; Plesa G; Lacey SF; Navenot JM; Zheng Z; Levine BL; Okada H; June CH; Brogdon JL; Maus MV
    Sci Transl Med; 2017 Jul; 9(399):. PubMed ID: 28724573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFRvIII-CAR-T Cells with PD-1 Knockout Have Improved Anti-Glioma Activity.
    Zhu H; You Y; Shen Z; Shi L
    Pathol Oncol Res; 2020 Oct; 26(4):2135-2141. PubMed ID: 31989402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants.
    Krenciute G; Prinzing BL; Yi Z; Wu MF; Liu H; Dotti G; Balyasnikova IV; Gottschalk S
    Cancer Immunol Res; 2017 Jul; 5(7):571-581. PubMed ID: 28550091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human EGFRvIII chimeric antigen receptor T cells demonstrate favorable safety profile and curative responses in orthotopic glioblastoma.
    Abbott RC; Iliopoulos M; Watson KA; Arcucci V; Go M; Hughes-Parry HE; Smith P; Call MJ; Cross RS; Jenkins MR
    Clin Transl Immunology; 2023; 12(3):e1440. PubMed ID: 36890859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR806-CAR T cells selectively target a tumor-restricted EGFR epitope in glioblastoma.
    Ravanpay AC; Gust J; Johnson AJ; Rolczynski LS; Cecchini M; Chang CA; Hoglund VJ; Mukherjee R; Vitanza NA; Orentas RJ; Jensen MC
    Oncotarget; 2019 Dec; 10(66):7080-7095. PubMed ID: 31903167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric Antigen Receptor T Cells in Glioblastoma-Current Concepts and Promising Future.
    Kringel R; Lamszus K; Mohme M
    Cells; 2023 Jul; 12(13):. PubMed ID: 37443804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice.
    Dong X; Ren J; Amoozgar Z; Lee S; Datta M; Roberge S; Duquette M; Fukumura D; Jain RK
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36898734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel high-affinity EGFRvIII-specific chimeric antigen receptor T cells effectively eliminate human glioblastoma.
    Abbott RC; Verdon DJ; Gracey FM; Hughes-Parry HE; Iliopoulos M; Watson KA; Mulazzani M; Luong K; D'Arcy C; Sullivan LC; Kiefel BR; Cross RS; Jenkins MR
    Clin Transl Immunology; 2021; 10(5):e1283. PubMed ID: 33976881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case Report: Prolonged Survival Following EGFRvIII CAR T Cell Treatment for Recurrent Glioblastoma.
    Durgin JS; Henderson F; Nasrallah MP; Mohan S; Wang S; Lacey SF; Melenhorst JJ; Desai AS; Lee JYK; Maus MV; June CH; Brem S; O'Connor RS; Binder Z; O'Rourke DM
    Front Oncol; 2021; 11():669071. PubMed ID: 34026647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
    Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z
    Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel EGFRvIII-CAR transgenic mice for rigorous preclinical studies in syngeneic mice.
    Chuntova P; Hou Y; Naka R; Yamamichi A; Chen T; Goretsky Y; Hatae R; Nejo T; Kohanbash G; Mende AL; Montoya M; Downey KM; Diebold D; Skinner J; Liang HE; Schwer B; Okada H
    Neuro Oncol; 2022 Feb; 24(2):259-272. PubMed ID: 34347086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arming Anti-EGFRvIII CAR-T With TGFβ Trap Improves Antitumor Efficacy in Glioma Mouse Models.
    Li Y; Wu H; Chen G; Wei X; Wang C; Zhou S; Huang A; Zhang Z; Zhan C; Wu Y; Ying T
    Front Oncol; 2020; 10():1117. PubMed ID: 32974124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.